Global Pharmatech, Inc. (GBLP) Research

Global Pharmatech, Inc., established in 2001 and based in Changchun, China, specializes in the research, development, and manufacturing of a broad spectrum of pharmaceutical products and dietary supplements. Operating primarily within China, the company's offerings include herbal, biological, chemical, and traditional Chinese medicines. Its key product portfolio features the XS CAPSULE (XIN-SHU), developed to treat angina and other coronary artery diseases; the JUTAI SOFT CAPSULE, a dietary aid; the QINGXUAN ANTI-HYPERTENSION TABLET, an over-the-counter medication addressing high blood pressure and elevated cholesterol; and the YANREQING TABLET, formulated to combat inflammation. Additionally, Global Pharmatech produces and distributes a variety of other branded and generic drugs, alongside supplements, designed to alleviate common ailments such as headaches, coughs, dry mouth, infections, and limb numbness. The firm employs a comprehensive distribution strategy, leveraging both its internal sales team and external channels, including wholesale companies and representatives from chain stores, to market its products.

Open Global Pharmatech, Inc. (GBLP) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.